Morepen Laboratories Ltd vs Wockhardt Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Morepen Laboratories Ltd is ₹ 41.41 as of 30 Apr 15:30 . The P/E Ratio of Morepen Laboratories Ltd changed from 14.9 on March 2021 to 22.3 on March 2025 . This represents a CAGR of 8.40% over 5 yearsThe P/E Ratio of Wockhardt Ltd changed from 6.7 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 years The Market Cap of Morepen Laboratories Ltd changed from ₹ 1446 crore on March 2021 to ₹ 2621 crore on March 2025 . This represents a CAGR of 12.64% over 5 yearsThe Market Cap of Wockhardt Ltd changed from ₹ 4590 crore on March 2021 to ₹ 23133 crore on March 2025 . This represents a CAGR of 38.19% over 5 years The revenue of Morepen Laboratories Ltd for the Dec '25 is ₹ 487.97 crore as compare to the Sep '25 revenue of ₹ 442.04 crore. This represent the growth of 10.39% The revenue of Wockhardt Ltd for the Dec '25 is ₹ 913 crore as compare to the Sep '25 revenue of ₹ 803 crore. This represent the growth of 13.7% The ebitda of Morepen Laboratories Ltd for the Dec '25 is ₹ 50.12 crore as compare to the Sep '25 ebitda of ₹ 61.16 crore. This represent the decline of -18.05% The ebitda of Wockhardt Ltd for the Dec '25 is ₹ 192 crore as compare to the Sep '25 ebitda of ₹ 199 crore. This represent the decline of -3.52% The net profit of Morepen Laboratories Ltd changed from ₹ 36.17 crore to ₹ 27.5 crore over 7 quarters. This represents a CAGR of -14.50% The net profit of Wockhardt Ltd changed from ₹ -16 crore to ₹ 61 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Morepen Laboratories Ltd changed from 10.79 % on March 2025 to 10.79 % on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe Dividend Payout of Wockhardt Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Morepen Laboratories Ltd

Morepen Laboratories Limited is an India-based pharmaceutical company.
Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin.
The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast.
It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India.
The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally.

About Wockhardt Ltd

Wockhardt Limited, incorporated in July, 1999 is a global pharmaceutical and biotechnology organization, providing affordable, high-quality medicines for a healthier world.
The Company is India's leading research-based global healthcare enterprise in fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals.
It has 12 manufacturing locations and there are 3 locations where research and development activities are carried out. The Company has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland.
It has a significant presence in USA, Europe and India, with 83% of its global revenues coming from international businesses.
Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified lnfectious Diseases Programme) for 5 of Anti-bacterial discovery programmes - 2 of them are Gram Negative and 3 Gram Positive effective against untreatable 'Superbugs'.

FAQs for the comparison of Morepen Laboratories Ltd and Wockhardt Ltd

Which company has a larger market capitalization, Morepen Laboratories Ltd or Wockhardt Ltd?

Market cap of Morepen Laboratories Ltd is 2,269 Cr while Market cap of Wockhardt Ltd is 22,661 Cr

What are the key factors driving the stock performance of Morepen Laboratories Ltd and Wockhardt Ltd?

The stock performance of Morepen Laboratories Ltd and Wockhardt Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Morepen Laboratories Ltd and Wockhardt Ltd?

As of May 3, 2026, the Morepen Laboratories Ltd stock price is INR ₹41.41. On the other hand, Wockhardt Ltd stock price is INR ₹1394.6.

How do dividend payouts of Morepen Laboratories Ltd and Wockhardt Ltd compare?

To compare the dividend payouts of Morepen Laboratories Ltd and Wockhardt Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.